Treatment of Cutaneous Larva Migrans with albendazole: preliminary report

Tratamiento del Síndrome de Larva Cutanea Migratoria con Albendazol: reporte Preliminar

Jaime R. Torres R. Angel R. Orihuela David Garcia Salha Abdul-Hadi

Abstracts

Twenty three patients with Cutaneous Larva Migrans syndrome were prospectively treated with 400 mg/day of Albendazole for 3 consecutive days. Clinical response, compliance and tolerance was excellent. Patients were asymptomatic within the first 72 hours of treatment and recurrences did not occurred. Preliminary results with three additional patients suggest that a single oral 400 mg dose may be effective as well.

Cutaneous larva migrans; Treatment; Albendazole


Veintitrés pacientes con el sindrome de Larva Cutanea Migratoria, fueron tratados prospectivamente con 400 mg/dia VO de albendazol por tres dias consecutivos. La respuesta clínica, aceptación y tolerancia del tratamiento fué excelente. Todos los pacientes se volvieron asintomáticos durante las primeras 72 horas de tratamiento y no se observaron recurrencias de lesiones. Los resultados preliminares obtenidos entres pacientes adicionales, sugieren que la dosis única de 400 mg puede ser igualmente efectiva.


PRELIMINARY REPORT

Treatment of Cutaneous Larva Migrans with albendazole. Preliminary report

Tratamiento del Síndrome de Larva Cutanea Migratoria con Albendazol. Reporte Preliminar

Jaime R. Torres R.; Angel R. Orihuela; David Garcia; Salha Abdul-Hadi

Address for correspondence

SUMMARY

Twenty three patients with Cutaneous Larva Migrans syndrome were prospectively treated with 400 mg/day of Albendazole for 3 consecutive days. Clinical response, compliance and tolerance was excellent. Patients were asymptomatic within the first 72 hours of treatment and recurrences did not occurred. Preliminary results with three additional patients suggest that a single oral 400 mg dose may be effective as well.

Key words: Cutaneous larva migrans; Treatment; Albendazole.

RESUMEN

Veintitrés pacientes con el sindrome de Larva Cutanea Migratoria, fueron tratados prospectivamente con 400 mg/dia VO de albendazol por tres dias consecutivos. La respuesta clínica, aceptación y tolerancia del tratamiento fué excelente. Todos los pacientes se volvieron asintomáticos durante las primeras 72 horas de tratamiento y no se observaron recurrencias de lesiones. Los resultados preliminares obtenidos entres pacientes adicionales, sugieren que la dosis única de 400 mg puede ser igualmente efectiva.

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

Recebido para publicação em 20/5/1988.

  • 1. BEAVER, P. C. - Larva Migrans. Exp. Parasit., 5: 587-594, 1956.
  • 2. BOHPALE, G. M. & BHATNAGAR, B. J. - The efficacy of some newer broad spectrum antihelminthics against third-stage larvae of Ancylostoma caninum in the mouse. J. Helminth., 59: 307 311, 1985.
  • 3. CLINE, B. L.; LITTLE, M. D.; BARTHOLOMEW, R. K. & HALSEY, N. A. - Larvicidal activity of albendazole against Necator americanus in human volunteers. Amer J. trop. Med. Hyg., 33: 387-394, 1984.
  • 4. DAVIS, C. M. & ISRAEL, R. M. - Treatment of creeping eruption with topical thiabendazole. Arch. Derm., 97: 325-329, 1968.
  • 5. WINTER P. A. & FRIPP, P. J. - Treatment of cutaneous larva migrans (sandworm disease). S. Afr. med. J., 52: 556-559, 1978.
  • 6. WRIGHT, D. O. & GOLD, E. M. - Loeffler's syndrome associated with creeping eruption. Arch, intern. Med., 78: 303-310, 1946.

  • Address for correspondence:
    Salha Abdul-Hadi
    Instituto de Medicina Tropical
    Universidad Central de Venezuela
    Apartado 2109, Caracas, Venezuela

Publication Dates

  • Publication in this collection
    18 Feb 2011
  • Date of issue
    Feb 1989

History

  • Received
    20 May 1988
Instituto de Medicina Tropical de São Paulo Av. Dr. Enéas de Carvalho Aguiar, 470, 05403-000 - São Paulo - SP - Brazil, Tel. +55 11 3061-7005 - São Paulo - SP - Brazil
E-mail: revimtsp@usp.br